Abstract
Human immunodeficiency virus (HIV-1) and hepatitis B virus (HBV) spread via similar transmission pathways, and infection by HBV occurs in up to 32% of HIV-1 cases. Here, we describe the successful expression of novel recombinant HIV-1/HBV virus-like particles (VLPs) in Nicotiana tabacum and Arabidopsis thaliana. The production levels and quality of the recombinant VLPs were comparable in the two plants, showing that parameters intrinsic to the recombinant proteins determined their assembly into VLPs. These heterologous VLPs can be used in a bivalent anti-HIV-1/-HBV vaccine, administrated via ingestion of transgenic plants.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
AIDS Vaccines / immunology
-
Arabidopsis / genetics
-
Arabidopsis / virology*
-
Cell Line, Tumor
-
HIV-1 / genetics*
-
HIV-1 / immunology
-
HIV-1 / metabolism
-
Hepatitis B Vaccines / immunology
-
Hepatitis B virus / genetics*
-
Hepatitis B virus / immunology
-
Hepatitis B virus / metabolism
-
Human Immunodeficiency Virus Proteins / biosynthesis*
-
Human Immunodeficiency Virus Proteins / genetics
-
Human Immunodeficiency Virus Proteins / immunology
-
Humans
-
Nicotiana / genetics
-
Nicotiana / virology*
-
Plants, Genetically Modified*
-
Recombinant Fusion Proteins / biosynthesis
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / immunology
-
Transgenes
-
Viral Proteins / biosynthesis*
-
Viral Proteins / genetics
-
Viral Proteins / immunology
Substances
-
AIDS Vaccines
-
Hepatitis B Vaccines
-
Human Immunodeficiency Virus Proteins
-
Recombinant Fusion Proteins
-
Viral Proteins